Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy

Award Number: R01CA293936
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2024
PERIOD OF PERFORMANCE END DATE: 07/31/2029

Group Awards By:

View Award Description

CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy - CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy Steinmetz (PI) and her colleagues have developed a plant virus nanoparticle immunotherapy that activates innate immune cells in the tumor microenvironment (TME) to launch adaptive, systemic, and durable antitumor immunity. Specifically, we found that nanoparticles based on cowpea mosaic virus (CPMV) stimulate a potent antitumor response in solid tumor mouse models and in canine cancer patients. Intratumoral immunotherapy CPMV overcomes immunosuppression within the TME launching adaptive antitumor immunity and immunological memory to prevent cancer recurrence. CPMV interacts with the immune system in a multivalent manner, resulting in a cascade of events boosted by avidity to achieve unprecedented potency. The intratumoral immunotherapy development pipeline is advancing quickly, but its effectiveness faces challenges, necessitating better delivery methods. Key issues include: (1) Large tumors often need more drugs or multiple injections, complicating procedures and possibly affecting therapy results due to variability. (2) High fluid pressure in tumors, caused by factors like vascular issues and confined cell growth, can impede drug delivery and even push drugs out of the tumor. (3) Frequent dosing can discomfort patients (and/or owner’s when patients are dogs), affecting their willingness to continue treatment. Therefore, we propose slow-release CPMV-polymer blend formulations for delivery as injectable devices. CPMV will be incorporated into polymer blends by applying scalable hot melt extrusion (HME) processing technology. Pokorski (MPI) is an expert in HME processing of biologics and our preliminary data confirm the structural and biological stability of CPMV released from the device technology. Finally, protein/polymer melts will be converted into injectable implants and microparticles using routinely available milling and molding equipment. We will fulfill the following aims: First, we will formulate CPMV-laden slow- release devices, establish and tune the release rates, confirm the structural integrity and biological activity released CPMV from the delivery technology. Second, we will perform clinical testing to establish efficacy, mechanism of action, and safety as a function of dose and delivery device. While the approach and CPMV intratumoral immunotherapy is tumor-agnostic, we will focus on metastatic breast cancer. To mimic a patient population with different subtypes of breast cancer, we will use immune-competent mouse models of metastatic disease including models of triple negative breast cancer, HER2+ and ER+/HER2- tumors. Third, as a prelude toward translation, we will perform a phase 0 canine trial enrolling canine patients with non- metastatic and metastatic mammary tumors; in collaboration with Co-I Peña. Companion dogs with spontaneous tumors provide a uniquely powerful resource that can be used for translational research as well as treatment of someone’s well-loved pet.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $638,352 )
2026	2026	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Cancer Detection and Diagnosis Research	000	3	6/23/2026	NON-COMPETING CONTINUATION	$638,352
														Subtotal = $638,352

Issue Date FY: 2025 ( Subtotal = $634,736 )
2025	2025	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Cancer Detection and Diagnosis Research	000	2	8/11/2025	NON-COMPETING CONTINUATION	$634,736
														Subtotal = $634,736

Issue Date FY: 2024 ( Subtotal = $619,294 )
2024	2024	UNIVERSITY OF CALIFORNIA, SAN DIEGO	9500 GILMAN DR	LA JOLLA	CA	92093	SAN DIEGO	USA	Cancer Detection and Diagnosis Research	000	1	7/18/2024	NEW	$619,294
														Subtotal = $619,294

Grand Total All Awards = $1,892,382

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy

Award Number: R01CA293936

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2024

PERIOD OF PERFORMANCE END DATE: 07/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer